Lon Smith

3.9k citations

35 papers · 2.5k indexed · 1 hit paper · h-index 17

Impact in

Oncology top 1%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Lung Cancer Research Studies
- Neutropenia and Cancer Infections
- Cancer Cells and Metastasis
Cancer Research top 5%
- Cancer Genomics and Diagnostics

Papers in ⓘ

Oncology 29
- Cancer Treatment and Pharmacology 7
- Pancreatic and Hepatic Oncology Research 7
- Colorectal Cancer Treatments and Studies 6
- HER2/EGFR in Cancer Research 6
- Lung Cancer Research Studies 5
Biotechnology 4
- Cancer Research and Treatments 4

Co-authors: Daniel D. Von Hoff (12 shared papers)Manuel Hidalgo (7 shared papers)John G. Kuhn (9 shared papers)John R. Eckardt (8 shared papers)Howard A. Burris (5 shared papers)Geoffrey R. Weiss (7 shared papers)Tina E. Wood (4 shared papers)Mitesh J. Borad (4 shared papers)
Journals: Journal of Clinical Oncology (21 papers)Clinical Cancer Research (3 papers)Breast Cancer Research and Treatment (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Cancers (1 paper)
Partner nations: United States France Japan

In The Last Decade

Lon Smith

35 papers receiving 2.5k citations

Hit Papers

align trajectories log scale

Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial 2011 · 823 citations

Peers

Countries citing papers authored by Lon Smith

Since Specialization

Citations

This map shows the geographic impact of Lon Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lon Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lon Smith more than expected).

Fields of papers citing papers by Lon Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lon Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lon Smith. The network helps show where Lon Smith may publish in the future.

Co-authors

The 25 scholars most cited alongside Lon Smith, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Lon Smith Line = papers co-authored together Lon Smith links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial Journal of Clinical Oncology ·Daniel D. Von Hoff, Ramesh K. Ramanathan, Mitesh J. Borad, Daniel A. Laheru, Lon Smith, Tina E. Wood, Ronald L. Korn, Neil Desai, Vuong Trieu, J. L. Mesías Iglesias, Hui Zhang, Patrick Soon‐Shiong, Tao Shi, N.V. Rajeshkumar, Anirban Maitra, Manuel Hidalgo Hit paper breakdown →	2011	823
2	The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer Clinical Cancer Research ·Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Drew Rasco, Lon Smith, Shelly Gunn, Leslie Smetzer, Theresa A. Mays, Brianne Kaiser, Michael J. Wick, Cathy Alvarez, Aracely Cavazos, G. Mangold, Amita Patnaik	2012	352
3	Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. Journal of Clinical Oncology ·Mace L. Rothenberg, John R. Eckardt, John G. Kuhn, Howard A. Burris, J. NELSON, Susan G. Hilsenbeck, G I Rodriguez, Allison Thurman, Lon Smith, S. Gail Eckhardt, Geoffrey R. Weiss, Gary Elfring, David Rinaldi, Larry J. Schaaf, Daniel D. Von Hoff	1996	305
4	Phase I and pharmacokinetic trial of weekly CPT-11. Journal of Clinical Oncology ·Mace L. Rothenberg, John G. Kuhn, Howard A. Burris, Joelle Nelson, John R. Eckardt, M Tristan-Morales, Susan G. Hilsenbeck, Geoffrey R. Weiss, Lon Smith, G I Rodriguez	1993	261
5	Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study Journal of Clinical Oncology ·Anthony W. Tolcher, Leonel Ochoa, Lisa A. Hammond, Amita Patnaik, Tam Edwards, Chris H. Takimoto, Lon Smith, Johann S. de Bono, Garry Schwartz, Theresa A. Mays, Zdenka Jonak, Randall S. Johnson, Mark DeWitte, Helen K. Martino, Charlene A. Audette, Kate Maes, Ravi Chari, John M. Lambert, Eric K. Rowinsky	2003	146
6	Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies Journal of Clinical Oncology ·Eric K. Rowinsky, Rachel Humphrey, Lisa A. Hammond, Cheryl Aylesworth, Leslie Smetzer, Manuel Hidalgo, Mark Morrow, Lon Smith, Allison M. Garner, John M. Sorensen, Daniel D. Von Hoff, S. Gail Eckhardt	2000	72
7	Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors Clinical Cancer Research ·Toshio Shimizu, Patricia LoRusso, K. Papadopoulos, Amita Patnaik, Muralidhar Beeram, Lon Smith, Drew Rasco, Theresa A. Mays, Glenda Chambers, Anna Ma, Jing Wang, Robert J Laliberte, Maurizio Voi, Anthony W. Tolcher	2014	67
8	Phase I study of MK-3475 (anti-PD-1 monoclonal antibody) in patients with advanced solid tumors. Journal of Clinical Oncology ·Amita Patnaik, Soonmo Peter Kang, Anthony W. Tolcher, Drew Rasco, Kyriakos P. Papadopoulos, Muralidhar Beeram, Ronald Drengler, Cong Chen, Lon Smith, C. Jordán Peréz, Kevin Gergich, M. Lehnert	2012	66
9	A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours European Journal of Cancer ·Jeffrey R. Infante, Kyriakos P. Papadopoulos, Johanna C. Bendell, Amita Patnaik, Howard A. Burris, Drew Rasco, Suzanne F. Jones, Lon Smith, Donna S. Cox, M. Durante, Kevin M. Bellew, Joo‐Hyun Park, Ngocdiep T. Le, Anthony W. Tolcher	2013	64
10	Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·S. Gail Eckhardt, Jinee Rizzo, Kevin Sweeney, G. Cropp, Sharyn D. Baker, Maura A. Kraynak, John G. Kuhn, Miguel A. Villalona‐Calero, Lisa A. Hammond, Geoffrey R. Weiss, Allison Thurman, Lon Smith, Ronald Drengler, John R. Eckardt, Judy Moczygemba, Alison L. Hannah, Daniel D. Von Hoff, Eric K. Rowinsky	1999	55
11	A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers The Oncologist ·Anthony W. Tolcher, Keith T. Flaherty, Geoffrey I. Shapiro, Jordan Berlin, Thomas E. Witzig, Thomas M. Habermann, Andrea J. Bullock, Edwin P. Rock, Agnes Elekes, Chester Lin, Dušan Kostic, Naoto Ohi, Drew Rasco, Kyriakos P. Papadopoulos, Amita Patnaik, Lon Smith, Gregory M. Coté	2018	50
12	Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion Anti-Cancer Drugs ·Howard A. Burris, Ahmad Awada, John G. Kuhn, John R. Eckardt, Patrick Cobb, David A Rlnaldi, Suzanne Fields, Lon Smith, Daniel D. Von Hoff	1994	40
13	Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel Journal of Clinical Oncology ·Manuel Hidalgo, Cheryl Aylesworth, Lisa A. Hammond, Carolyn D. Britten, Geoffrey R. Weiss, Joseph Stephenson, Garry Schwartz, Amita Patnaik, Lon Smith, Kathleen Molpus, Sally Felton, Elora Gupta, Karen J. Ferrante, Anne Tortora, Daryl Sonnichsen, Jamey Skillings, Eric K. Rowinsky	2001	33
14	A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms Clinical Cancer Research ·Lisa A. Hammond, John R. Eckardt, John G. Kuhn, Stanton L. Gerson, T J Johnson, Lon Smith, Ronald Drengler, Elizabeth Campbell, Geoffrey R. Weiss, Daniel D. Von Hoff, Eric K. Rowinsky	2004	27
15	Phase I dose-escalation of the oral MEK1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral AKT inhibitor GSK2141795 (GSK795). Journal of Clinical Oncology ·Razelle Kurzrock, Akash Patnaik, Laurence Rosenstein, Sidney W. Fu, Kyriakos P. Papadopoulos, Deborah A. Smith, G. S. Falchook, Glenda Chambers, Jennifer Gauvin, Aung Naing, Lon Smith, Teresita Pérez González, Apostolia M. Tsimberidou, Theresa A. Mays, Donna S. Cox, David S. Hong, Douglas J. DeMarini, N.T. Le, Shannon R. Morris, A. W. Tolcher	2011	26
16	Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study Cancer Chemotherapy and Pharmacology ·Jordi Rodón, Mitchell Garrison, Lisa A. Hammond, Johann S. de Bono, Lon Smith, Leonardo Forero, Desirée Hao, Chris H. Takimoto, John M. Lambert, Lini Pandite, Maria Howard, Hongsheng Xie, Anthony W. Tolcher	2008	25
17	Genotypic and allelic frequencies of SULT1A1 polymorphisms in women receiving adjuvant tamoxifen therapy Breast Cancer Research and Treatment ·Jodi L. Grabinski, Lon Smith, Gary B. Chisholm, Ronald Drengler, Gladys Rodriguez, Anna Lång, S. Kalter, Allison M. Garner, Lisa Fichtel, J. Hollsten, Bradley H Pollock, John G. Kuhn	2005	19
18	A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. PubMed ·Don W Shaffer, Lon Smith, H.A. Burris, Gary M. Clark, John R. Eckardt, Suzanne M. Fields, Geoffrey R. Weiss, David Rinaldi, Karen J. Bowen, J. Kuhn	1993	14
19	A Phase I and pharmacokinetics study of 2-chlorodeoxyadenosine in patients with solid tumors Cancer Chemotherapy and Pharmacology ·Geoffrey R. Weiss, John G. Kuhn, Jinee Rizzo, Lon Smith, Gladys Rodriguez, John R. Eckardt, Howard A. Burris, Suzanne Fields, Karla VanDenBerg, Daniel D. Von Hoff	1995	12
20	Final results of phase Ib of anticancer stem cell antibody tarextumab (OMP-59R5, TRXT, anti-Notch 2/3) in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC). Journal of Clinical Oncology ·Eileen M. O’Reilly, Lon Smith, Johanna C. Bendell, John H. Strickler, Mark M. Zalupski, William Larry Gluck, Ann M. Kapoun, Wan-Ching Yen, Lu Xu, Dawn Hill, Lei Zhou, Jakob Dupont, Allen Lee Cohn	2015	10

About Lon Smith

Lon Smith is a scholar working on Oncology, Biotechnology, Cancer Research, Genetics and Pharmacy, having authored 35 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (7 papers), Pancreatic and Hepatic Oncology Research (7 papers), Colorectal Cancer Treatments and Studies (6 papers), HER2/EGFR in Cancer Research (6 papers), Lung Cancer Research Studies (5 papers), Cancer therapeutics and mechanisms (4 papers), Cancer Research and Treatments (4 papers) and Estrogen and related hormone effects (4 papers). The work is most often cited by research in Oncology (1.8k citations), Cancer Research (452 citations), Molecular Biology (1.1k citations), Hepatology (113 citations) and Pulmonary and Respiratory Medicine (429 citations). Lon Smith has collaborated with scholars based in United States, France and Japan. Frequent co-authors include Daniel D. Von Hoff, Manuel Hidalgo, John G. Kuhn, John R. Eckardt, Howard A. Burris, Geoffrey R. Weiss, Tina E. Wood, Mitesh J. Borad, Daniel A. Laheru and Amita Patnaik. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Breast Cancer Research and Treatment, Cancer Chemotherapy and Pharmacology and Cancers.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact